Rani Therapeutics Holdings annual operating margin
2020
2021
2024
2025
Rani Therapeutics Holdings's operating margin was −2,345.99% for fiscal 2025.
View full Rani Therapeutics Holdings company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −2,345.99% | +2840.20 pp |
| 2024 | 2024-12-31 | −5,186.19% | −3287.07 pp |
| 2021 | 2021-12-31 | −1,899.12% | +1681.84 pp |
| 2020 | 2020-12-31 | −3,580.95% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −516.86% | +938.10 pp |
| Q1 2026 | 2026-03-31 | −488.23% | −220.10 pp |
| Q4 2025 | 2025-12-31 | −584.19% | +103.38 pp |
| Q1 2025 | 2025-03-31 | −6,984.30% | −4366.71 pp |
| Q4 2024 | 2024-12-31 | −1,454.96% | +4195.04 pp |
| Q2 2021 | 2021-06-30 | −268.13% | — |
| Q1 2021 | 2021-03-31 | −687.57% | — |
| Q3 2020 | 2020-09-30 | −2,617.59% | — |
| Q2 2020 | 2020-06-30 | −5,650.00% | — |
Across the available reported history, Rani Therapeutics Holdings's operating margin increased from −5,186.19% to −2,345.99%, a change of +2840.20 percentage points. The latest reported quarter, Q2 2026, shows −516.86%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Rani Therapeutics Holdings filings at SEC.gov ↗